Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more
Pacific Biosciences of California (PACB) - Total Assets
Latest total assets as of December 2025: $784.08 Million USD
Based on the latest financial reports, Pacific Biosciences of California (PACB) holds total assets worth $784.08 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pacific Biosciences of California - Total Assets Trend (2008–2025)
This chart illustrates how Pacific Biosciences of California’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pacific Biosciences of California - Asset Composition Analysis
Current Asset Composition (December 2025)
Pacific Biosciences of California's total assets of $784.08 Million consist of 47.8% current assets and 52.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.1% |
| Accounts Receivable | $35.45 Million | 4.5% |
| Inventory | $49.28 Million | 6.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $15.12 Million | 1.9% |
| Goodwill | $317.76 Million | 40.5% |
Asset Composition Trend (2008–2025)
This chart illustrates how Pacific Biosciences of California's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pacific Biosciences of California's current assets represent 47.8% of total assets in 2025, a decrease from 94.5% in 2008.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2025, down from 69.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 40.5% of total assets.
Pacific Biosciences of California Competitors by Total Assets
Key competitors of Pacific Biosciences of California based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Pacific Biosciences of California - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Pacific Biosciences of California generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pacific Biosciences of California is currently not profitable relative to its asset base.
Pacific Biosciences of California - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.89 | 7.48 | 35.45 |
| Quick Ratio | 5.99 | 6.59 | 34.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $320.62 Million | $ 429.38 Million | $ 1.16 Billion |
Pacific Biosciences of California - Advanced Valuation Insights
This section examines the relationship between Pacific Biosciences of California's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 77.91 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | -37.8% |
| Total Assets | $784.08 Million |
| Market Capitalization | $404.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pacific Biosciences of California's assets below their book value (0.52 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pacific Biosciences of California's assets decreased by 37.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pacific Biosciences of California (2008–2025)
The table below shows the annual total assets of Pacific Biosciences of California from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $784.08 Million | -37.79% |
| 2024-12-31 | $1.26 Billion | -27.81% |
| 2023-12-31 | $1.75 Billion | -1.19% |
| 2022-12-31 | $1.77 Billion | -11.95% |
| 2021-12-31 | $2.01 Billion | +384.80% |
| 2020-12-31 | $413.98 Million | +179.74% |
| 2019-12-31 | $147.99 Million | -13.09% |
| 2018-12-31 | $170.28 Million | +18.18% |
| 2017-12-31 | $144.08 Million | +4.50% |
| 2016-12-31 | $137.88 Million | +5.17% |
| 2015-12-31 | $131.11 Million | +5.29% |
| 2014-12-31 | $124.52 Million | -8.56% |
| 2013-12-31 | $136.19 Million | +5.01% |
| 2012-12-31 | $129.68 Million | -40.60% |
| 2011-12-31 | $218.32 Million | -28.60% |
| 2010-12-31 | $305.75 Million | +202.43% |
| 2009-12-31 | $101.10 Million | -10.62% |
| 2008-12-31 | $113.11 Million | -- |